医院与社区卫生服务模式的探索与实现

研究利用当代信息网络技术,探索实现医院与所辖社区卫生服务模式,为社区居民到上级医院就诊提供惠民的“绿色通道”.分析了社区卫生服务模式现状,详细介绍了医院与所辖社区卫生服务模式的实现,包括关键技术实现和系统功能,阐述了医院与所辖社区卫生服务模式取得的成效,并对下一步工作进行了展望.     

基于远程会诊的糖尿病视网膜病变图像诊断系统研发和应用

目的：开发远程糖尿病视网膜病变图像诊断系统,提高基层和社区医护人员的诊断水平,解决糖尿病视网膜病变管理的问题。方法：借用互联网计算机辅助诊疗技术,建立糖尿病视网膜病变的眼底图像数据库,采集糖尿病患者的眼底图像,进行分析对比,给出图文诊断报告。结果：开发了一套远程糖尿病视网膜病变图像诊断系统,在我院医疗联合体成功应用。结论：利用此系统利于基层医生全面掌握糖尿病视网膜病变诊疗技术,为降低盲残人群做出贡献。     

生物化学动画库的构建及其应用

针对生物化学学科特点和Flash独特的优势，结合教学实际，构建了生物化学Flash动画库，提供了一批形象直观的动画，并应用于生物化学的教学实践，充分显示了Flash在提高生物化学教学质量方面所具有的潜力。     

关注miRNA及相关肿瘤数据库在肿瘤研究中的应用

肿瘤是一种严重威胁人类健康的疾病,其发生发展历经漫长而复杂的过程。深入探究肿瘤分子发病机制将有助于肿瘤早期诊断和开发新的抗肿瘤药物。小核糖核酸(miRNA)是一种小片段的RNA,它通过抑制靶基因表达影响肿瘤的发展进程。本文以miRNA为中心,系统阐述miRNA参与肿瘤进程的分子机制,miRNA在肿瘤治疗以及循环miRNA在肿瘤早期诊断和预后评估方面的应用前景;数据库在肿瘤相关分子机制研究及筛选肿瘤发展进程中miRNA调控关键基因的应用。希望通过本文与广大研究工作者共同努力推动肿瘤的机制研究。     

基于Sybase的HIS系统数据库死锁原因浅析

基于Sybase的医院信息系统（HIS）在开发及维护过程中,都遇到过各种死锁问题的困扰。引起数据库死锁的原因有多种,分析了引起Sybase数据库死锁原因,从而为解决死锁问题理清了思路。     

基于网络药理学及生物信息学研究骨碎补-淫羊藿治疗骨质疏松的作用机制

目的 基于网络药理学和生物信息学探讨"骨碎补-淫羊藿"治疗骨质疏松的分子机制,为骨质疏松治疗提供新的靶点.方法 通过TCMSP数据库筛选"骨碎补-淫羊藿"的活性成分,联合UniProt数据库预测其调控靶点,并根据GEO数据库预测治疗骨质疏松的靶点.借助R语言获取治疗骨质疏松的有效靶点,并构建"药物-成分-靶点-通路"网...     

LIS系统与东方旗云软件联合用于细菌耐药性统计优势

目的寻找准确、便捷的细菌耐药性统计系统。方法通过东方旗云软件与实验室细菌鉴定仪的连接,将细菌药敏结果直接导如whonet系统。结果可以准确、简便、快捷的统计细菌耐药性,以便监测细菌耐药趋势,合理指导临床用药。结论东方旗云软件可LIS系统联合在实验室信息系统管理与细菌耐药性统计方面有重要实用价值。     

Monitoring Emerging Diseases of Fish and Shellfish Using Electronic Sources

New and emerging fish and shellfish diseases represent an important constraint to the growth and sustainability of many aquaculture sectors and have also caused substantial economic and environmental impacts in wild stocks. This paper details the results of 8 years of a monitoring programme for emerging aquatic animal diseases reported around the world. The objectives were to track global occurrences and, more specifically, to identify and provide advanced warning of disease threats that may affect wild and farmed fish stocks in the UK. A range of electronic information sources, including Internet newsletters, alerting services and news agency releases, was systematically searched for reports of new diseases, new presentations of known pathogens and known diseases occurring in new geographic locations or new host species. A database was established to log the details of key findings, and 250 emerging disease events in 52 countries were recorded during the period of study. These included 14 new diseases and a further 16 known diseases in new species. Viruses and parasites accounted for the majority of reports (55% and 24%, respectively), and known diseases occurring in new locations were the most important emerging disease category (in which viruses were dominant). Emerging diseases were reported disproportionally in salmonid species (33%), in farmed populations (62%) and in Europe and North America (80%). The lack of reports from some regions with significant aquaculture or fishery production may indicate that emerging diseases are not being recognized in these areas owing to insufficient surveillance or testing or that these events are being under‐reported. The results are discussed in relation to processes underpinning disease emergence in the aquatic environment.     

Health care expenditures for Medicaid‐covered males with haemophilia in the United States, 2008

Summary. Although haemophilia is an expensive disorder, no studies have estimated health care costs for Americans with haemophilia enrolled in Medicaid as distinct from those with employer‐sponsored insurance (ESI). The objective of this study is to provide information on health care utilization and expenditures for publicly insured people with haemophilia in the United States in comparison with people with haemophilia who have ESI. Data from the MarketScan^® Medicaid Multi‐State, Commercial and Medicare Supplemental databases were used for the period 2004?2008 to identify cases of haemophilia and to estimate medical expenditures during 2008. A total of 511 Medicaid‐enrolled males with haemophilia were identified, 435 of whom were enrolled in Medicaid for at least 11 months during 2008. Most people with haemophilia qualified for Medicaid based on ‘disability’. Average Medicaid expenditures in 2008 were $142,987 [median, $46,737], similar to findings for people with ESI. Average costs for males with haemophilia A and an inhibitor were 3.6 times higher than those for individuals without an inhibitor. Average costs for 56 adult Medicaid enrollees with HCV or HIV infection were not statistically different from those for adults without the infection, but median costs were 1.6 times higher for those treated for blood‐borne infections. Haemophilia treatment can lead to high costs for payers. Further research is needed to understand the effects of public health insurance on haemophilia care and expenditures, to evaluate treatment strategies and to implement strategies that may improve outcomes and reduce costs of care.